Adam Gibb

672 total citations
15 papers, 390 citations indexed

About

Adam Gibb is a scholar working on Oncology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Adam Gibb has authored 15 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 5 papers in Epidemiology. Recurrent topics in Adam Gibb's work include Lymphoma Diagnosis and Treatment (10 papers), Viral-associated cancers and disorders (6 papers) and Herpesvirus Infections and Treatments (4 papers). Adam Gibb is often cited by papers focused on Lymphoma Diagnosis and Treatment (10 papers), Viral-associated cancers and disorders (6 papers) and Herpesvirus Infections and Treatments (4 papers). Adam Gibb collaborates with scholars based in United Kingdom, United States and Italy. Adam Gibb's co-authors include Gunhild L. Vejlsgaard, Neil Bodsworth, John Radford, Kim Linton, Tim Illidge, P D Woolley, R Patel, Seppo Saari, B Peters and S. Kulkarni and has published in prestigious journals such as Blood, The Journal of Urology and British Journal of Cancer.

In The Last Decade

Adam Gibb

15 papers receiving 368 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adam Gibb United Kingdom 11 175 160 145 92 51 15 390
Imran Shahab United States 12 148 0.8× 79 0.5× 149 1.0× 41 0.4× 113 2.2× 20 430
Lucia Alba Italy 10 184 1.1× 116 0.7× 228 1.6× 53 0.6× 166 3.3× 16 421
Daniel Gillor Germany 10 134 0.8× 103 0.6× 170 1.2× 102 1.1× 212 4.2× 15 407
Magid Herida France 6 111 0.6× 135 0.8× 195 1.3× 14 0.2× 103 2.0× 6 336
P Blanché France 9 62 0.4× 141 0.9× 59 0.4× 21 0.2× 115 2.3× 30 339
Giovanna Travi Italy 11 44 0.3× 218 1.4× 97 0.7× 76 0.8× 174 3.4× 27 418
Laura Monfort France 10 75 0.4× 205 1.3× 73 0.5× 55 0.6× 25 0.5× 21 355
J. W. Mugerwa Uganda 9 118 0.7× 190 1.2× 277 1.9× 36 0.4× 142 2.8× 11 503
Jutta Preiksaitis Canada 9 98 0.6× 330 2.1× 264 1.8× 11 0.1× 208 4.1× 12 620
V. Rémy France 9 36 0.2× 307 1.9× 33 0.2× 23 0.3× 18 0.4× 18 445

Countries citing papers authored by Adam Gibb

Since Specialization
Citations

This map shows the geographic impact of Adam Gibb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Gibb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Gibb more than expected).

Fields of papers citing papers by Adam Gibb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Gibb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Gibb. The network helps show where Adam Gibb may publish in the future.

Co-authorship network of co-authors of Adam Gibb

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Gibb. A scholar is included among the top collaborators of Adam Gibb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Gibb. Adam Gibb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Derenzini, Enrico, Adam Gibb, Michał Kwiatek, & Paolo Strati. (2025). Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: drug profile and expert opinion on the prevention and management of adverse events. Leukemia & lymphoma. 66(11). 1990–2002. 1 indexed citations
2.
3.
Radford, John, Felipe A. Castro, Anshuman Chaturvedi, et al.. (2019). Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre. Blood. 134(Supplement_1). 2917–2917. 5 indexed citations
4.
Jones, Nicholas P., et al.. (2017). Gamma–delta T-cell lymphoma of skin, eye and brain presenting with visual loss. BMJ Case Reports. 2017. bcr–2017. 2 indexed citations
5.
Gibb, Adam, Graham P. Collins, Rakesh Popat, et al.. (2017). BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). Hematological Oncology. 35(S2). 67–67. 31 indexed citations
6.
Gibb, Adam, Sarah Pirrie, Kim Linton, et al.. (2017). RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY). Hematological Oncology. 35(S2). 80–81. 10 indexed citations
7.
Eyre, Toby A., Elizabeth H. Phillips, Kim Linton, et al.. (2017). Results of a multicentre UK‐wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. British Journal of Haematology. 179(3). 471–479. 15 indexed citations
8.
Illidge, Tim, Réda Bouabdallah, Robert Chen, et al.. (2014). Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leukemia & lymphoma. 56(3). 703–710. 26 indexed citations
9.
Gibb, Adam, Alastair Greystoke, Malcolm Ranson, et al.. (2013). A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. British Journal of Cancer. 109(10). 2560–2565. 6 indexed citations
10.
11.
Creighton, Sarah, et al.. (2008). The impact of establishing a local-enhanced service for treating sexually transmitted infections in primary care. Sexually Transmitted Infections. 84(3). 235–238. 13 indexed citations
12.
Bodsworth, Neil, R. J. Crooks, Sueli Donizete Borelli, et al.. (1998). Valaciclovir Versus Aciclovir in Patient Initiated Treatment of Recurrent Genital Herpes: A Randomised, Double Blind Clinical Trial. The Journal of Urology. 159(4). 1420–1421. 17 indexed citations
13.
Patel, R, Neil Bodsworth, P D Woolley, et al.. (1998). Valaciclovir for the Suppression of Recurrent Genital HSV Infection: A Placebo Controlled Study of Once Daily Therapy. The Journal of Urology. 159(4). 1421–1421. 25 indexed citations
14.
Bodsworth, Neil, R. J. Crooks, Sueli Donizete Borelli, et al.. (1997). Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group.. Sexually Transmitted Infections. 73(2). 110–116. 71 indexed citations
15.
Patel, R, Neil Bodsworth, P D Woolley, et al.. (1997). Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group.. Sexually Transmitted Infections. 73(2). 105–109. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Imran Shahab Breakdown of academic impact, for papers by Lucia Alba Breakdown of academic impact, for papers by Daniel Gillor Breakdown of academic impact, for papers by Magid Herida Breakdown of academic impact, for papers by P Blanché Breakdown of academic impact, for papers by Giovanna Travi Breakdown of academic impact, for papers by Laura Monfort Breakdown of academic impact, for papers by J. W. Mugerwa Breakdown of academic impact, for papers by Jutta Preiksaitis Breakdown of academic impact, for papers by V. Rémy
Rankless by CCL
2026